AxoSim is pioneering the development of advanced in vitro models that replicate the human brain and nervous system, addressing the significant shortcomings of traditional animal models in neurological drug testing. Their innovative products, such as the central nervous system microBrain™ and BrainSim®, as well as the peripheral nervous system NerveSim®, utilize a combination of neurons, astrocytes, microglia, and other cell types to create realistic environments for studying various neurological diseases. These models provide clinically-relevant electrophysiological data, enabling researchers to assess drug safety and efficacy with over 90% accuracy in predicting human outcomes, a stark contrast to the mere 30% accuracy of conventional methods.

The company's unique platform integrates tissue engineering, neural interfacing, and artificial intelligence to facilitate the rapid screening of potential therapeutic interventions. By leveraging 3D human brain organoids and proprietary neural interfaces, AxoSim captures the intricate dynamics of neurological processes, allowing for a more comprehensive understanding of conditions such as neurodegeneration, neuropathy, and pain disorders. This approach not only enhances the translational potential of drug discovery but also aims to improve the quality of life for individuals affected by neurological diseases, aligning with AxoSim's vision of preserving identity and independence in the face of such challenges.

United States

AxoSim empowers advancements in human neuroscience by partnering with biopharma companies to facilitate breakthroughs in devastating neurological diseases and disorders. Their proprietary drug discovery platforms NerveSim®, BrainSim®, and microBrain™  deliver clinically-relevant data to select better lead candidates with phenotypically accurate assays. AxoSim's platforms have applications in peripheral neuropathy and neuropathic pain, disease modeling (such as ALS, MS, and CMT), and neurotoxicology. 

AxoSim

Company Details